Pharma Mar, S.A.
PHM
Rank in Stocks
#8009
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and... Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Share Price
$63.40
Last synced: 2026-11-20
Market Cap
$1.10B
Change (1 day)
-2.39%
Change (1 year)
-27.22%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pharma Mar, S.A. (PHM)
Category
Healthcare
Operating Margin for Pharma Mar, S.A. (PHM)
Operating Margin as of November 2026 TTM: 19.57%
According to Pharma Mar, S.A.'s latest financial reports, its current operating margin (TTM) is 19.57%. At the end of 2025 the company had an operating margin of 18.19%.
Operating Margin history for Pharma Mar, S.A. from 2002 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 19.57% | 7.59% |
| 2025 | 18.19% | 391.62% |
| 2024 | 3.70% | -252.89% |
| 2023 | -2.42% | -110.78% |
| 2022 | 22.45% | -44.18% |
| 2021 | 40.22% | -30.38% |
| 2020 | 57.77% | -383.74% |
| 2019 | -20.36% | 134.56% |
| 2018 | -8.68% | -11.97% |
| 2017 | -9.86% | -4.64% |
| 2016 | -10.34% | -275.85% |
| 2015 | 5.88% | -56.80% |
| 2014 | 13.61% | 0.89% |
| 2013 | 13.49% | 27.99% |
| 2012 | 10.54% | 127.65% |
| 2011 | 4.63% | -174.68% |
| 2010 | -6.20% | -76.29% |
| 2009 | -26.15% | -25.71% |
| 2008 | -35.20% | -33.63% |
| 2007 | -53.04% | -15.77% |
| 2006 | -62.97% | -96.47% |
| 2005 | -1,782.80% | 37.08% |
| 2004 | -1,300.60% | 3,666.58% |
| 2003 | -34.53% | -48.66% |
| 2002 | -67.26% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 33.87% | -98.27% |
US
|
|
| -116.04% | -105.93% |
US
|
|
| 25.57% | -98.69% |
AU
|
|
| 29.35% | -98.50% |
NL
|
|
| 31.23% | -98.40% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pharma Mar, S.A.'s operating margin
What is Pharma Mar, S.A.'s operating margin?
Pharma Mar, S.A.'s operating margin is 19.57%, as of Nov 2026.
What was Pharma Mar, S.A.'s operating margin in 2025?
In 2025, Pharma Mar, S.A.'s operating margin was 18.19%, compared with 3.70% in 2024.
How has Pharma Mar, S.A.'s operating margin changed since 2020?
From 2020 to 2025, Pharma Mar, S.A.'s operating margin was highest in 2020 (57.77%) and lowest in 2023 (-2.42%).
How does Pharma Mar, S.A.'s operating margin compare with similar companies?
Pharma Mar, S.A.'s operating margin (19.57%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.